Engitix Ltd. lands US$500m deal with Takeda in fibrosis
British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
Moderna set to deliver COVID-19 jab to the EU
US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists map ulcerative colitis
Scientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
COVID-19: Roche and Regeneron join forces
Roche and Regeneron have signed an manufacturing and distribution agreement on Regenerons Phase II therapeutic antibody for the treatment of COVID-19.
Aicuris to launch AiCubator to fight AMR
Antinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
AI predicts mutations underlying neurological diseases
Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.
F2G bags 50.8m financing to advance olorofim
UK-Austrian fungal infection specialist F2G Ltd has secured a 50.8m (US $60.8m) financing from new and existing investors.
Evotec receives $8.4m CARB-X funding
Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.